Trials / Completed
CompletedNCT04381117
Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)
A Phase 2b, Open-label Long-term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the long-term safety and duration of efficacy of CCH in the treatment of women with cellulite. This study will be a single day evaluation, approximately 48 months after the first dose of study drug was received in the EN3835-201.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Previously Treated with EN3835 | No treatment to be administered - Observational only |
Timeline
- Start date
- 2020-05-06
- Primary completion
- 2020-06-22
- Completion
- 2020-06-22
- First posted
- 2020-05-08
- Last updated
- 2024-01-02
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04381117. Inclusion in this directory is not an endorsement.